Primary Sclerosing Cholangitis
On this page
Direct answer
A beaded, pruned-tree biliary tree on MRCP — multifocal strictures alternating with dilatations involving intrahepatic and extrahepatic ducts — in a patient with ulcerative colitis identifies primary sclerosing cholangitis (PSC), a progressive fibro-obliterative cholangiopathy for which no medical therapy has been shown to improve survival. Around 70-80 percent of PSC patients have inflammatory bowel disease (usually ulcerative pancolitis, often quiescent), and the duct disease precedes, accompanies or follows the colitis in any order. Management is surveillance and complication management: MRCP (or ERCP where tissue or therapy is needed) establishes the anatomy, dominant strictures are brushed and stented with cholangitis episodes treated promptly, high-dose UDCA is expressly not recommended, annual cholangiocarcinoma and gallbladder surveillance by imaging (with CA 19-9) is standard, and liver transplantation — the only cure — is offered for decompensation, intractable pruritus or recurrent cholangitis.
What you must remember
- Cholangiographic signature: multifocal short strictures with intervening dilatations producing a beaded or pruned-tree appearance across both intra- and extrahepatic ducts; a beak-like dominant stricture raises cholangiocarcinoma until brushed and imaged.
- The IBD axis: ulcerative colitis in 70-80 percent (pancolitis typically mild), and conversely PSC in a small but important fraction of colitis patients — PSC-associated colitis carries higher colorectal cancer risk, demanding annual colonoscopy from diagnosis.
- Malignancy arithmetic to quote: cholangiocarcinoma develops in roughly 10-20 percent lifetime (highest in the first years after diagnosis), gallbladder cancer risk justifies annual ultrasound with cholecystectomy for any gallbladder polyp over 8 mm, and colorectal surveillance is annual.
- What not to prescribe: high-dose UDCA (28-30 mg/kg/day) increased death and transplant need in trials and is contraindicated; standard-dose UDCA is neither recommended as therapy nor proven harmful — the exam tests the high-dose point.
- Dominant stricture protocol: ERCP with brush cytology (with FISH for aneuploidy where available), short-term stenting for biliary obstruction, antibiotics for cholangitis — and a low threshold for PET/CT or cholangioscopy when malignancy is suspected.
- The great mimic — IgG4-related sclerosing cholangitis: an older man with a pancreatic mass or retroperitoneal fibrosis, raised serum IgG4, dense lymphoplasmacytic infiltrate on biopsy, and a swift steroid response — must be excluded before accepting PSC, because the treatments are opposite.
- Small-duct PSC: cholestatic enzymes and compatible histology with a normal cholangiogram — better prognosis, lower cholangiocarcinoma risk, but still IBD-associated and still monitored.
- Transplant triggers: model for end-stage liver disease-based decompensation, intractable pruritus, recurrent cholangitis and early hilar cholangiocarcinoma under selected protocols; PSC recurs in the graft in a minority.
Why there is no medical therapy
A 33-year-old man with a six-year history of quiescent ulcerative colitis presents with pruritus and an ALP of 520; MRCP shows diffuse beading of intrahepatic ducts with a dominant extrahepatic stricture. The consultation is dominated by what cannot be offered: no drug — not UDCA at any tested dose, not immunosuppressants — has improved transplant-free survival in PSC, because the disease is fibrotic rather than inflammatory by the time it declares itself. What can be offered is a surveillance architecture: annual MRI with CA 19-9 for cholangiocarcinoma, annual ultrasound for gallbladder disease, annual colonoscopy for the PSC-colitis colon risk, fat-soluble vitamin replacement, cholestyramine for itch, and ERCP when the dominant stricture obstructs or cholangitis recurs. His serum IgG4 is checked early and is normal, excluding the steroid-responsive mimic; a brush cytology from the stricture is negative for malignancy. The long arc ends, for many, at transplantation — which he is listed for when bilirubin trends upward and bacterial cholangitis recurs.
The examinable irony: medicine's job in PSC is to watch the ducts, treat the complications, catch the cancers early — and know what not to prescribe.
Where candidates slip
The dominant error is prescribing UDCA as if PSC were PBC — the diseases share cholestatic enzymes and itch, but high-dose UDCA harms in PSC, and even standard dosing is not recommended therapy; the exam answer is surveillance, not ursodeoxycholic acid. The second slip is forgetting ERCP's double edge: it provides brushings and stenting but each pass risks cholangitis in an obstructed system, so prophylactic antibiotics and selective use are the rule. Third, the IgG4 mimic — any older man with "PSC" plus pancreatic disease or a raised IgG4 needs biopsy and a steroid trial rather than a transplant workup. Indian candidates should also hold intestinal tuberculosis in mind: a strictured, beaded duct picture with ileocaecal disease can coexist with TB-related stricturing, and conflating tuberculous strictures with PSC on imaging is a reported trap in tropical practice.
Frequently asked questions
What cholangiographic pattern defines primary sclerosing cholangitis?
Multifocal short strictures alternating with segmental dilatations — a beaded, pruned-tree appearance — involving intrahepatic and often extrahepatic ducts on MRCP or ERCP.
Why is high-dose UDCA not used in PSC?
Because trials of high-dose ursodeoxycholic acid (around 28-30 mg/kg/day) showed increased mortality and transplant rates, and no dose has demonstrated survival benefit — unlike its central role in primary biliary cholangitis.
What cancers does PSC predispose to and how are they screened?
Cholangiocarcinoma (lifetime risk roughly 10-20 percent, screened by annual imaging with CA 19-9), gallbladder carcinoma (annual ultrasound, cholecystomy for polyps over 8 mm) and colorectal cancer in IBD (annual colonoscopy).
How is a dominant stricture managed?
ERCP with brush cytology and short-term stenting to relieve obstruction, antibiotics for cholangitis, and escalation to cholangioscopy, PET or transplantation assessment when cytology or imaging suggests cholangiocarcinoma.
Which condition mimics PSC but responds to steroids?
IgG4-related sclerosing cholangitis — raised serum IgG4, lymphoplasmacytic infiltration on biopsy, often with autoimmune pancreatitis, treated with corticosteroids rather than surveillance.